SAB Biotherapeutics gets FDA Fast Track for T1D therapy SAB-142
The designation applies to SAB-142 in new-onset Stage 3 type 1 diabetes, as the company's Phase 2b and investigator-led Phase 3 studies continue.
SEC filing
Latest
1 story
Sign inSign in1 story
The designation applies to SAB-142 in new-onset Stage 3 type 1 diabetes, as the company's Phase 2b and investigator-led Phase 3 studies continue.
SEC filing